Business
Protext Pharma to Conduct Clinical Trial to Determine Therapeutic Dosage Levels for Treating Diabetes
Protext Pharma to Conduct Clinical Trial to Determine Therapeutic Dosage Levels for Treating Diabetes.
About this update from Protext Mobility, Inc.
[{"type":"text","content":"\n \n \n Protext Pharma to Conduct Clinical Trial to Determine Therapeutic Dosage Levels for Treating Diabetes\n \n \nProtext Pharma to Conduct Clinical Trial to Determine Therapeutic Dosage Levels for Treating Diabetes\n\nCompany's Near Term Goal to Sell Phytofare® as a Primary Therapy Protocol\n\n \n BOCA RATON, FL--(Marketwired - Sep 13, 2017) - Protext Pharma, Inc. (OTC PINK: TXTM) (\"Protext\" or \"the Company\"), a biotech company engaged in the development of pharmaceutical botanical medicines that are formulated with highly-bioavailable plant extracts, today announced that, following extensive investigations with scientists at a leading United States diabetic research institute, the company is modifying its forthcoming diabetes study protocols. The studies will focus on establishing an effective therapeutic dosage point for Phytofare® catechin complex as a first line protocol for Type 2 diabetes while also investigating whether Phytofare® catechins can prevent or manage Type 1 diabetes. The Company's near-term goal is to market Phytofare®, which has been clinically proven to have superior bioavailability, as a primary therapy with specific structure-function claims based on forthcoming study results.\n Phytofare® catechin complex is a clinically-proven highly bioavailable extract produced from live green tea leaf, containing all 8 catechins or antioxidants found in green tea. Human studies have shown that Phytofare® catechins have twelve-times greater bioavailability over generic catechin extracts, where they are delivered protected to the blood plasma and remained at therapeutic levels for more than 24 hours. This suggests that Phytofare® can achieve favorable clinical effects at low oral daily dosage levels.\n  Roger Baylis-Duffield, Chief Executive Officer of Protext Pharma, commented, \"In addition to working with CIDP on defining our human clinical trial for Type 2 diabetes, we have been collaborating with a team of leading diabetes researchers based in the US to standardize an investigation model to confirm Phytofare® catechin complex as a primary prevention strategy for autoimmune diabetes and as a glucose regulator for Type 2 diabetes. We want to focus our research on establishing an effective therapeutic dosage point for Phytofare® catechin co...